Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: The MaxCmin1 and 2 trials

Basic and Clinical Pharmacology and Toxicology

Volumn 101, Issue 5, 2007, Pages 339-344

  Justesen, Ulrik S ^a   Fox, Zoe ^b   Pedersen, Court ^a   Cahn, Pedro ^c   Gerstoft, Jan ^d   Clumeck, Nathan ^e   Losso, Marcello ^f   Peters, Barry ^g   Obel, Niels ^d,h   Castagna, Antonella ⁱ   Dragsted, Ulrik B ^b   Lundgren, Jens D ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Guest Foundation   (Argentina)

^d Rigshospitalet   (Denmark)

^e SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^f HOSPITAL RAMOS MEJÍA   (Argentina)

^g ST THOMAS HOSPITAL   (United Kingdom)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; INDINAVIR; LOPINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; SAQUINAVIR; TREATMENT FAILURE;

EID: 34848893678     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00117.x     Document Type: Article

References (23)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997 126 : 946 54.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997 337 : 725 33.
3. Gulick RM, Mellors JW, Havlir D et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000 133 : 35 9.
4. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003 362 : 22 9.
5. Dragsted UB, Gerstoft J, Pedersen C et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 trial. J Infect Dis 2003 188 : 635 42.
6. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002 346 : 2039 46.
7. Fletcher CV, Anderson PL, Kakuda TN et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002 16 : 551 60.
8. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002 16 : 2311 5.
9. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003 17 : 1157 65.
10. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006 28 : 468 73.
11. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003 51 : 1231 8.
12. + T-cell counts in HIV-infected patients. Ann Intern Med 1996 124 : 1039 50.
13. Gatti G, Di Biagio A, Casazza R et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999 13 : 2083 9.
14. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999 13 : 473 8.
15. Solas C, Basso S, Poizot-Martin I et al. High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr 2002 29 : 374 7.
16. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001 2 : 105 13.
17. Dragsted UB, Gerstoft J, Youle M et al. A randomised trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: the MaxCmin2 Trial. Antivir Ther 2005 10 : 735 43.
18. Gisolf EH, van Heeswijk RP, Hoetelmans RW, Danner SA. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000 14 : 801 5.
19. Justesen US, Pedersen C, Klitgaard NA. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003 783 : 491 500.
20. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother 2002 46 : 884 6.
21. Gill J, Feinberg J. Saquinavir soft gelatin capsule: a comparative safety review. Drug Saf 2001 24 : 223 32.
22. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003 2 : 624 34.
23. Gutierrez F, Padilla S, Navarro A, Masia M, Hernandez I. Lipid abnormalities in HIV-infected patients and lopinavir plasma concentrations. J Acquir Immune Defic Syndr 2004 36 : 1107 9.